EGFR and non-small cell lung adenocarcinoma: For instance, detection of plasma-derived EGFR mutation of advanced or metastatic non-small cell lung adenocarcinoma (NSCLC) patients is helpful for the treatment with EGFR tyrosine kinase inhibitors (TKIs) [20].